A case-control study of 53 patients receiving HER2-targeted therapy further found that an LVEF <55% at any surveillance timepoint was associated with higher risk for HF, suggesting that baseline cardiac function might be an important factor that determines the cardiac outcome (120). Here, ERBB2 is linked to hydrops fetalis.